Christine I. Wooddell

Dr. Christine I. Wooddell

Arrowhead Pharmaceuticals
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
CWChristine I. Wooddell
Christine I. Wooddell
MYMan-Fung Yuen
Man-Fung Yuen
HCHenry Lik-Yuen Chan
Henry Lik-Yuen Chan
RGRobert G. Gish
Robert G. Gish
SLStephen A. Locarnini
Stephen A. Locarnini
DLDavid L. Lewis
David L. Lewis
The hepatitis B virus surface antigen, key to maintaining chronic infection, is expressed from viral DNA integrated into the host chromosome.

1 May 2013 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
CWChristine I. Wooddell
Christine I. Wooddell
DRDavid B Rozema
David B Rozema
MHMarkus Hossbach
Markus Hossbach
MJMatthias John
Matthias John
HHHolly L Hamilton
Holly L Hamilton
DLDavid L Lewis
David L Lewis
RNA interference (RNAi)-based therapeutics have the potential to treat chronic hepatitis B virus (HBV) infection in a fundamentally different manner than current therapies. Using RNAi, it is possible to knock down expression of viral RNAs including the pregenomic RNA from which the replicative intermediates are derived, thus reducing viral load, and the viral proteins that result in disease and impact the immune system's ability to eliminate the virus. We previously described the use of polymer-based Dynamic PolyConjugate (DPC) for the targeted delivery of siRNAs to hepatocytes. Here, we first show in proof-of-concept studies that simple coinjection of a hepatocyte-targeted, N-acetylgalactosamine-conjugated melittin-like peptide (NAG-MLP) with a liver-tropic cholesterol-conjugated siRNA (chol-siRNA) targeting coagulation factor VII (F7) results in efficient F7 knockdown in mice and nonhuman primates without changes in clinical chemistry or induction of cytokines. Using transient and transgenic mouse models of HBV infection, we show that a single coinjection of NAG-MLP with potent chol-siRNAs targeting conserved HBV sequences resulted in multilog repression of viral RNA, proteins, and viral DNA with long duration of effect. These results suggest that coinjection of NAG-MLP and chol-siHBVs holds great promise as a new therapeutic for patients chronically infected with HBV.

1 May 2011 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
CPChristophe Pichavant
Christophe Pichavant
AAAnnemieke Aartsma-Rus
Annemieke Aartsma-Rus
PCPaula R Clemens
Paula R Clemens
KDKay E Davies
Kay E Davies
GDGeorge Dickson
George Dickson
Jacques P. TremblayJacques P. Tremblay
Jacques P. Tremblay
Duchenne muscular dystrophy (DMD) is a genetic disease affecting about one in every 3,500 boys. This X-linked pathology is due to the absence of dystrophin in muscle fibers. This lack of dystrophin leads to the progressive muscle degeneration that is often responsible for the death of the DMD patients during the third decade of their life. There are currently no curative treatments for this disease but different therapeutic approaches are being studied. Gene therapy consists of introducing a transgene coding for full-length or a truncated version of dystrophin complementary DNA (cDNA) in muscles, whereas pharmaceutical therapy includes the use of chemical/biochemical substances to restore dystrophin expression or alleviate the DMD phenotype. Over the past years, many potential drugs were explored. This led to several clinical trials for gentamicin and ataluren (PTC124) allowing stop codon read-through. An alternative approach is to induce the expression of an internally deleted, partially functional dystrophin protein through exon skipping. The vectors and the methods used in gene therapy have been continually improving in order to obtain greater encapsidation capacity and better transduction efficiency. The most promising experimental approaches using pharmaceutical and gene therapies are reviewed in this article.

1 September 2015 in Antiviral Research
Verified
Journal Article
Open access
RGRobert G. Gish
Robert G. Gish
MYMan-Fung Yuen
Man-Fung Yuen
HCHenry Lik Yuen Chan
Henry Lik Yuen Chan
BGBruce D. Given
Bruce D. Given
Ching-Lung LaiChing-Lung Lai
Ching-Lung Lai
DLDavid L. Lewis
David L. Lewis
Current therapies for chronic hepatitis B virus infection (CHB) - nucleos(t)ide analogue reverse transcriptase inhibitors and interferons - result in low rates of functional cure defined as sustained off-therapy seroclearance of hepatitis B surface antigen (HBsAg). One likely reason is the inability of these therapies to consistently and substantially reduce the levels of viral antigen production. Accumulated evidence suggests that high serum levels of HBsAg result in exhaustion of the host immune system, rendering it unable to mount the effective antiviral response required for HBsAg clearance. New mechanistic approaches are required to produce high rates of HBsAg seroclearance in order to greatly reduce off-treatment disease progression. Already shown to be a clinically viable means of reducing gene expression in a number of other diseases, therapies based on RNA interference (RNAi) can directly target hepatitis B virus transcripts with high specificity, profoundly reducing the production of viral proteins. The fact that the viral RNA transcripts contain overlapping sequences means that a single RNAi trigger can result in the degradation of all viral transcripts, including all messenger RNAs and pregenomic RNA. Advances in the design of RNAi triggers have increased resistance to degradation and reduced nonspecific innate immune stimulation. Additionally, new methods to effectively deliver the trigger to liver hepatocytes, and specifically to the cytoplasmic compartment, have resulted in increased efficacy and tolerability. An RNAi-based drug currently in clinical trials is ARC-520, a dynamic polyconjugate in which the RNAi trigger is conjugated to cholesterol, which is coinjected with a hepatocyte-targeted, membrane-active peptide. Phase 2a clinical trial results indicate that ARC-520 was well tolerated and resulted in significant, dose-dependent reduction in HBsAg for up to 57days in CHB patients. RNAi-based therapies may play an important role in future therapeutic regimes aimed at improving HBsAg seroclearance and eliminating the need for lifelong therapy. This paper forms part of a symposium in Antiviral Research on "An unfinished story: from the discovery of the Australia antigen to the development of new curative therapies for hepatitis B."

18 June 2020 in JCI Insight
Verified
Journal Article
Closed access
PDF file
CWChristine I. Wooddell
Christine I. Wooddell
KBKeith Blomenkamp
Keith Blomenkamp
RPRyan M. Peterson
Ryan M. Peterson
VSVladimir Subbotin
Vladimir Subbotin
CSChristian Schwabe
Christian Schwabe
JTJeffrey H. Teckman
Jeffrey H. Teckman
The autosomal codominant genetic disorder alpha-1 antitrypsin (AAT) deficiency (AATD) causes pulmonary and liver disease. Individuals homozygous for the mutant Z allele accumulate polymers of Z-AAT protein in hepatocytes, where AAT is primarily produced. This accumulation causes endoplasmic reticulum (ER) stress, oxidative stress, damage to mitochondria, and inflammation, leading to fibrosis, cirrhosis, and hepatocellular carcinoma. The magnitude of AAT reduction and duration of response from first-generation intravenously administered RNA interference (RNAi) therapeutic ARC-AAT and then with next-generation subcutaneously administered ARO-AAT were assessed by measuring AAT protein in serum of the PiZ transgenic mouse model and human volunteers. The impact of Z-AAT reduction by RNAi on liver disease phenotypes was evaluated in PiZ mice by measuring polymeric Z-AAT in the liver; expression of genes associated with fibrosis, autophagy, apoptosis, and redox regulation; inflammation; Z-AAT globule parameters; and tumor formation. Ultrastructure of the ER, mitochondria, and autophagosomes in hepatocytes was evaluated by electron microscopy. In mice, sustained RNAi treatment reduced hepatic Z-AAT polymer, restored ER and mitochondrial health, normalized expression of disease-associated genes, reduced inflammation, and prevented tumor formation. RNAi therapy holds promise for the treatment of patients with AATD-associated liver disease. ARO-AAT is currently in phase II/III clinical trials.

10 March 2008 in The Journal of Gene Medicine
Verified
Journal Article
Closed access
PDF file
CWChristine I. Wooddell
Christine I. Wooddell
TRThomas Reppen
Thomas Reppen
JWJon A. Wolff
Jon A. Wolff
HHHans Herweijer
Hans Herweijer